STAAのチャート
STAAの企業情報
symbol | STAA |
---|---|
会社名 | Staar Surgical Co. (スタ―サ―ジカル) |
分野(sector) | Health Care ヘルスケア |
産業(industry) | Ophthalmic Goods |
業種 | 医療機器_医療用品_ディストリビュ―タ― 医療関連(Health Care) |
概要 | 事業概要 スター・サージカル(STAAR Surgical Company)は、眼科用移植型レンズ及び眼内にレンズを送達するために使用される送達システムを設計・開発・生産・販売している。同社は眼手術市場セグメントで事業を展開する。主な製品は、白内障手術に使用される眼内レンズと、屈折矯正手術で使用される埋め込み型コラーマーレンズである。同社は、矯正手術と屈折矯正手術で世界中で使用されているレンズを作り、白内障を治療する手術で使用するレンズを作る。その屈折矯正手術は、眼鏡またはコンタクトレンズが治療している視覚障害(近視、遠視、乱視および老視)のタイプを矯正する。同社は米国、カナダ、日本、スペインでの直接販売、世界の残りの地域での独立した販売など、75カ国以上で製品を販売している。 スタ―サ―ジカルは、眼内に移植可能なレンズを開発、製造、販売する米国の会社。矯正や屈折矯正手術で使用されるレンズのメ―カ―である。白内障を治療する手術に使用するためのレンズも製造。同社が開発するすべてのレンズは折りたたみ可能で、手術の際、小さな切開部からも挿入可能である。主要製品のブランド名は、「STAAR」「Collamer」など。 STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's lens used in refractive surgery is called an Implantable Collamer® Lens or 'ICL', which includes the EVO Visian ICL™ product line. More than 1,000,000 Visian® ICLs have been implanted to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: www.discovericl.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. |
本社所在地 | 1911 Walker Avenue Monrovia CA 91016 USA |
代表者氏名 | Louis E. Silverman ルイE.シルバーマン |
代表者役職名 | Independent Chairman of the Board |
電話番号 | +1 626-303-7902 |
設立年月日 | 30225 |
市場名 | NASDAQ National Market System |
ipoyear | ―年 |
従業員数 | 353人 |
url | www.staar.com |
nasdaq_url | https://www.nasdaq.com/symbol/staa |
adr_tso | ― |
EBITDA | EBITDA(百万ドル) 6.48900 |
終値(lastsale) | 41.54 |
時価総額(marketcap) | 1825489215.9 |
時価総額 | 時価総額(百万ドル) 1770.969 |
売上高 | 売上高(百万ドル) 109.32300 |
企業価値(EV) | 企業価値(EV)(百万ドル) 1756.707 |
当期純利益 | 当期純利益(百万ドル) 9.10600 |
決算概要 | 決算概要 BRIEF: For the six months ended 29 June 2018 STAAR Surgical Company revenues increased 44% to $61M. Net income totaled $2.4M vs. loss of $3.2M. Revenues reflect China segment increase from $10.3M to $21.9M Others segment increase of 28% to $23.4M. Net Income reflects Royalty income increase of 18% to $306K (income) Interest expense decrease of 40% to $36K (expense). |
STAAのテクニカル分析
STAAのニュース
A stock that deserves closer examination: STAAR Surgical Company (STAA) 2023/02/02 16:24:00 US Post News
A share of STAAR Surgical Company (NASDAQ:STAA) closed at $72.96 per share on Wednesday, up from $70.55 day before. While STAAR Surgical Company has overperformed by 3.42%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, STAA rose by 0.33%, with highs and lows ranging from $112.27 […]
STAAR Surgical Company: Getting Ahead Of Itself In 2023 (NASDAQ:STAA) 2023/02/01 17:44:15 Seeking Alpha
Shares of implantable lens manufacturer STAAR Surgical had fallen over 55% since August but are rebounding. Click here for our analysis of STAA stock.
STAAR Surgical PT Raised to $80 at Canaccord Genuity 2023/01/30 12:34:01 Investing.com
https://www.investing.com/news/pro/staar-surgical-pt-raised-to-80-at-canaccord-genuity-432SI-2991093
STAAR Surgical Company (NASDAQ: STAA) Stock: Boom Or Bust? What Happens Next? 2023/01/19 20:00:00 Marketing Sentinel
During the recent session, STAAR Surgical Company (NASDAQ:STAA)’s traded shares were 0.48 million, with the beta value of the company hitting 1.08. At the last check today, the stock’s price was $65.96, reflecting an intraday loss of -6.72% or -$4.75. The 52-week high for the STAA share is $112.27, that puts it down -70.21 from … STAAR Surgical Company (NASDAQ: STAA) Stock: Boom Or Bust? What Happens Next? Read More »
STAAR Surgical Company (NASDAQ: STAA) Surged -5.40% In 6 Months – Here’s What Happens Next 2023/01/14 12:00:00 Marketing Sentinel
STAAR Surgical Company (NASDAQ:STAA)’s traded shares stood at 0.73 million during the last session, with the company’s beta value hitting 1.05. At the close of trading, the stock’s price was $72.50, to imply an increase of 3.13% or $2.2 in intraday trading. The STAA share’s 52-week high remains $112.27, putting it -54.86% down since that … STAAR Surgical Company (NASDAQ: STAA) Surged -5.40% In 6 Months – Here’s What Happens Next Read More »
STAAR Surgical: Data Approach Justifies Portfolio Allocation 2022/07/05 19:15:51 Seeking Alpha
STAAR Surgical (STAA) presents with the fundamental momentum that we feel can drive equity returns into the coming years. See why we rate STAA stock a buy.
STAAR Surgical Company (NASDAQ: STAA) Stock Price Forecast: $100 2022/06/25 14:00:00 Stocks Register
STAAR Surgical Company (NASDAQ:STAA) shares, rose in value on Friday, 06/24/22, with the stock price up by 3.72% to the previous day’s close as strong demand from buyers drove the stock to $74.78. Actively observing the price movement in the last trading, the stock closed the session at $72.10, falling within a range of $71.00 … STAAR Surgical Company (NASDAQ: STAA) Stock Price Forecast: $100 Read More »
STAAR Surgical Celebrates Two Million Lens Milestone for Implantable Collamer Lens (ICL) 2022/06/07 11:00:00 Wallstreet:Online
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that more than two million Visian Implantable Collamer lenses (“ICLs”) have been sold globally, including more than one and a half million of the company’s latest generation of implantable lenses – EVO Visian ICLs (“EVO”).
STAAR Surgical Celebrates Two Million Lens Milestone for Implantable Collamer® Lens (ICL) 2022/06/07 11:00:00 Business Wire
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that more than two million Visian® Implantable Collamer lenses (“ICLs”) have been sold globally, including more than one and a half million of the company’s latest generation of implantable lenses – EVO Visian® ICLs (“EVO”). New to the U.S. market, EVO is available in more than 75 countries a
STAAR Surgical Company (NASDAQ: STAA) Stock Gained 12.14% Over A Month – Any Room To Run? 2022/05/28 16:00:00 Marketing Sentinel
STAAR Surgical Company (NASDAQ:STAA)’s traded shares stood at 0.35 million during the last session, with the company’s beta value hitting 1.13. At the close of trading, the stock’s price was $67.04, to imply an increase of 6.65% or $4.18 in intraday trading. The STAA share’s 52-week high remains $163.08, putting it -143.26% down since that … STAAR Surgical Company (NASDAQ: STAA) Stock Gained 12.14% Over A Month – Any Room To Run? Read More »
Intraocular Lens Market Generated Opportunities, Future Scope 2021-2028 | STAAR Surgical Company, HOYA Corporation, Lenstec, Inc. 2021/12/24 07:53:54 OpenPR
Another factual information on the "Intraocular Lens Market" has as of late added by CMI to its storehouse. This global research report offers an inside and out examination of various perspectives, for example, global market patterns, pieces of the overall
Stephens Inc. AR Sells 1,712 Shares of STAAR Surgical (NASDAQ:STAA) 2021/12/22 09:40:45 Dakota Financial News
Stephens Inc. AR trimmed its holdings in shares of STAAR Surgical (NASDAQ:STAA) by 23.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,636 shares of the medical instruments suppliers stock after selling 1,712 shares during the period. Stephens Inc. ARs holdings in []
Strs Ohio Reduces Stake in STAAR Surgical (NASDAQ:STAA) 2021/12/18 10:04:41 Dakota Financial News
Strs Ohio trimmed its stake in STAAR Surgical (NASDAQ:STAA) by 21.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,200 shares of the medical instruments suppliers stock after selling 3,400 shares during the quarter. Strs Ohios holdings in STAAR []
$59.30 Million in Sales Expected for STAAR Surgical (NASDAQ:STAA) This Quarter 2021/12/15 03:16:42 Transcript Daily
Equities analysts expect STAAR Surgical (NASDAQ:STAA) to report sales of $59.30 million for the current quarter, Zacks reports. Three analysts have made estimates for STAAR Surgicals earnings, with estimates ranging from $59.10 million to $59.40 million. STAAR Surgical posted sales of $46.00 million during the same quarter last year, which suggests a positive year-over-year growth []
STAAR Surgical (NASDAQ:STAA) CTO Keith Holliday Sells 6,000 Shares 2021/12/15 01:50:43 Transcript Daily
STAAR Surgical (NASDAQ:STAA) CTO Keith Holliday sold 6,000 shares of the firms stock in a transaction on Tuesday, December 14th. The shares were sold at an average price of $89.57, for a total transaction of $537,420.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Shares of []